KVP Capital Advisors, LP
CIK 1858198 · 在 SEC EDGAR 上查看 ↗
- 投资组合价值
- $136.2M
- 持仓
- 35
- 截至
- 2026年6月30日
按 13F 价值排名第 7684（共 9443） · 前 81.4%
投资组合价值同比（季度）：+1.7% 13F不披露现金
- 前十大持仓权重
- 57.41%
- 前二十五大持仓权重
- 89.22%
- 持仓高于 1%
- 32
- 有效持仓数量
- 22.2
仅基于13F多头股票持仓（现金、债券、空头未披露）
周转率 Q2 2026: 13.86% 估计买入 $18714663 · 卖出 $37982560
- 新仓位
- 6
- 增加
- 2
- 减少
- 2
- 已结清
- 3
本页内容
行业细分
Healthcare
100.0%
完整投资组合 35 持仓
| 类型 | 连胜 | 8个季度趋势 | |||||
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. - Common Stock | $14362491 | 10.54% | 42900 | $540540 | |||
| WHWK Whitehawk Therapeutics, Inc. - Common Stock | $9920266 | 7.28% | 2165997 | $2447576 | |||
| ERAS Erasca, Inc. - Common Stock | $8335600 | 6.12% | 455000 | $2834400 | 上涨 ×1 | ||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $7721100 | 5.67% | 414000 | $2782080 | |||
| STRO Sutro Biopharma, Inc. - Common Stock | $7522290 | 5.52% | 226575 | $1878307 | |||
| TNGX Tango Therapeutics, Inc. - Common Stock | $7198053 | 5.28% | 230264 | $2380930 | |||
| MBX MBX Biosciences, Inc. - Common Stock | $6708125 | 4.92% | 121524 | $3080634 | |||
| PTGX Protagonist Therapeutics, Inc. - Common Stock | $6496740 | 4.77% | 53000 | $910540 | |||
| EWTX Edgewise Therapeutics, Inc. - Common Stock | $5403790 | 3.97% | 133000 | $1214290 | |||
| TNDM Tandem Diabetes Care, Inc. - Common Stock | $4542090 | 3.33% | 301000 | 上涨 ×1 | |||
| IRON Disc Medicine, Inc. - Common Stock | $4260405 | 3.13% | 58250 | $535900 | |||
| SVRA Savara, Inc. - Common Stock | $3728525 | 2.74% | 605280 | $423696 | |||
| AVBP ArriVent BioPharma, Inc. - Common Stock | $3543480 | 2.60% | 102000 | 上涨 ×1 | |||
| INSM Insmed Incorporated - Common Stock | $3038350 | 2.23% | 28497 | $-1621479 | |||
| ACHV Achieve Life Sciences, Inc. - Common Shares | $3019178 | 2.22% | 462355 | $1659854 | |||
| IDYA IDEAYA Biosciences, Inc. - Common Stock | $2970419 | 2.18% | 79700 | $314815 | |||
| OCUL Ocular Therapeutix, Inc. - Common Stock | $2946000 | 2.16% | 300000 | $405000 | |||
| AXSM Axsome Therapeutics, Inc. - Common Stock | $2937240 | 2.16% | 12000 | $-3181284 | 下跌 ×1 | ||
| DSGN Design Therapeutics, Inc. - Common Stock | $2676950 | 1.96% | 185000 | 上涨 ×1 | |||
| UTHR United Therapeutics Corporation - Common Stock | $2573693 | 1.89% | 4750 | $-242962 | |||
| SRRK Scholar Rock Holding Corporation - Common Stock | $2475000 | 1.82% | 45000 | $262800 | |||
| IMMX Immix Biopharma, Inc. - Common Stock | $2375661 | 1.74% | 230423 | $276507 | |||
| VRDN Viridian Therapeutics, Inc. - Common Stock | $2296250 | 1.69% | 125000 | $-148750 | |||
| MLYS Mineralys Therapeutics, Inc. - Common Stock | $2270853 | 1.67% | 84168 | 上涨 ×1 | |||
| DRUG Bright Minds Biosciences Inc. - common stock | $2233273 | 1.64% | 31813 | $-88122 | |||
| TVTX Travere Therapeutics, Inc. - Common Stock | $2215590 | 1.63% | 39000 | $-488020 | 下跌 ×1 | ||
| ZURA Zura Bio Limited - Class A Ordinary shares | $2201455 | 1.62% | 373128 | $-18657 | |||
| ARTV Artiva Biotherapeutics, Inc. - Common Stock | $1940000 | 1.42% | 200000 | 上涨 ×1 | |||
| NKTR Nektar Therapeutics - Common Stock | $1877889 | 1.38% | 26900 | $-57566 | |||
| CMPX Compass Therapeutics, Inc. - Common Stock | $1688490 | 1.24% | 771000 | $-956510 | 上涨 ×1 | ||
| CABA Cabaletta Bio, Inc. - Common Stock | $1571890 | 1.15% | 505431 | $212281 | |||
| VERA Vera Therapeutics, Inc. - Class A Common Stock | $1403157 | 1.03% | 32700 | $87636 | |||
| EOLS Evolus, Inc. - Common Stock | $1041000 | 0.76% | 150000 | 上涨 ×1 | |||
| CELC Celcuity Inc. - Common Stock | $418480 | 0.31% | 4000 | $-38080 | |||
| VYNE VYNE Therapeutics Inc. - Common Stock | $325709 | 0.24% | 500551 | $26630 | |||
| 无匹配项 | |||||||
最大新仓位
本季度新开仓位，按规模从大到小排序。
季度涨幅榜
已退出持仓
包含公司事件（合并、退市）——并非所有退出都是卖出
已关闭的头寸反映了 13F 报告的变更；对于指数管理人来说，这些通常是机械性的（退市、并购、指数再平衡），而不是主动决策。